COVID-19 Side Effects: Short and Long-Term Symptoms

COVID-19 produces a wide spectrum of effects that range from a few days of mild cold-like symptoms to organ damage detectable months or years after the initial infection. During the acute phase, fever, cough, fatigue, and loss of smell are among the most recognized signs, but the virus can also attack the gut, the heart, and the brain. For a significant minority of people, symptoms do not resolve when the infection clears, a condition broadly called long COVID or post-acute sequelae of SARS-CoV-2 (PASC). The story of COVID-19’s side effects is really two stories: the short, often self-limiting illness, and the longer, less predictable aftermath.

What the Acute Illness Looks Like

The short-term symptoms most people associate with COVID-19 are respiratory: cough, sore throat, congestion, and shortness of breath. Fever and body aches round out the classic picture. But the virus does not limit itself to the airways. One of the more distinctive early symptoms is anosmia, a sudden loss of smell. Research has traced this to the virus’s attack on sustentacular cells, the support cells in the lining of the nose that help olfactory neurons function.¹ When those support cells become infected, the resulting inflammation damages the cilia on smell-sensing neurons and reduces their ability to send signals to the brain.² For most people, smell returns within weeks, but for some it takes months or comes back distorted.

Gastrointestinal symptoms are another major piece of the acute picture that often gets overlooked. Nausea, diarrhea, and abdominal pain are common because the receptor the virus uses to enter cells is highly expressed on the surface of small intestinal cells.³ The virus can invade and replicate in the gut lining, causing local inflammation and sometimes intestinal bleeding.⁴ This gut involvement also explains why viral material shows up in stool samples, sometimes well after respiratory symptoms have cleared, and it becomes relevant to the long COVID story.

How Long COVID Develops and How Long It Lasts

Long COVID is generally defined as symptoms that persist or newly appear at least four weeks after infection. The range of reported symptoms is strikingly broad, spanning fatigue, brain fog, heart palpitations, joint pain, shortness of breath, and dozens more. One of the most detailed looks at the trajectory of these symptoms comes from a large study that followed over 135,000 people with confirmed SARS-CoV-2 infection for three years, comparing them against more than five million uninfected controls. Among those whose initial infection did not require hospitalization, the elevated risk of death disappeared after the first year, and the risk of developing new long COVID symptoms declined over time but still contributed meaningfully to health loss in the third year.⁵

For people who were hospitalized, the picture was grimmer. Their risk of death declined but remained elevated even three years out, and the residual burden of ongoing health problems was roughly ten times higher than in the non-hospitalized group.⁵ The key takeaway is that long COVID is not a single fixed condition but a gradient: many people recover over months, some improve but retain lingering issues, and a smaller group remains substantially impaired years later.

What Drives Symptoms After the Infection Clears

Researchers have identified several overlapping mechanisms that may explain why the body keeps misfiring long after the virus should be gone. No single mechanism accounts for every case, which is part of why long COVID looks so different from person to person.

One leading hypothesis is viral persistence. Fragments of SARS-CoV-2 RNA and viral proteins have been detected in the gut, cardiovascular tissue, and other organs months after the initial illness.⁶ Whether those remnants represent a low-grade ongoing infection or just leftover molecular debris is still debated, but either way, their presence appears to provoke a chronic immune response. A recent study using tissue biopsies from long COVID patients found evidence of immune dysregulation in the gut consistent with the body trying to fight something that is still there, though direct viral detection occurred in only a subset of participants.⁷

A second mechanism involves autoimmunity. The virus may trigger the immune system to produce antibodies that mistakenly target the body’s own tissues. Research has identified cross-reactive antibodies that bind to both viral proteins and human proteins, which could help explain why some long COVID symptoms resemble autoimmune diseases.⁸

A third thread is vascular damage. During acute infection, the virus injures the endothelial cells that line blood vessels throughout the body, promoting tiny blood clots and disrupting the barriers between the bloodstream and organs including the brain, lungs, and kidneys.⁹ In some patients, this endothelial dysfunction persists into convalescence, contributing to ongoing symptoms.¹⁰ Researchers have also identified unusual fibrin-based microclots in the blood of long COVID patients, loaded with inflammatory molecules, that may physically obstruct small blood vessels and starve tissues of oxygen.¹¹

Fatigue and Post-Exertional Malaise

If there is a single symptom that defines the long COVID experience for most people, it is fatigue, and not ordinary tiredness. Many long COVID patients describe a bone-deep exhaustion that does not improve with rest. Worse, physical or mental exertion can trigger a dramatic crash in the following hours or days, a phenomenon called post-exertional malaise. In one observational study, about 59% of long COVID participants met the scoring thresholds for post-exertional malaise used to diagnose myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).¹²

The overlap between long COVID and ME/CFS is not coincidental. Post-exertional malaise is increasingly recognized as a shared feature of both conditions, and researchers are exploring whether the same metabolic and cardiovascular abnormalities underlie both.¹³ For patients, the practical consequence is that the conventional advice to gradually increase exercise can backfire. Pushing through fatigue may worsen symptoms rather than build stamina, a pattern that distinguishes post-exertional malaise from ordinary deconditioning.

Cardiovascular Effects and Autonomic Dysfunction

Heart-related complaints, including chest pain, palpitations, and exercise intolerance, are among the most common long COVID symptoms. Some of these trace back to the endothelial and clotting damage described earlier, but another major culprit is dysautonomia, a malfunction of the autonomic nervous system that controls heart rate, blood pressure, and other involuntary functions.¹⁴

The most talked-about form of this is postural orthostatic tachycardia syndrome, or POTS, where standing up causes the heart rate to spike abnormally. In a study of highly symptomatic long COVID patients, about 31% met the diagnostic criteria for POTS. Those patients were predominantly female, younger on average, and had significantly lower physical activity and shorter walking distances during a six-minute walk test compared to long COVID patients without POTS.¹⁵ POTS is not dangerous in itself, but it can be profoundly disabling, leaving people unable to stand for long, exercise, or work at a desk without feeling faint and exhausted.

Lung Damage After Recovery

Because COVID-19 is fundamentally a respiratory disease, it is no surprise that the lungs bear some of the heaviest long-term damage. The concern that has drawn the most clinical attention is pulmonary fibrosis, where inflammation during the acute phase leads to scarring of the lung tissue.¹⁶ Scar tissue is stiff and cannot exchange oxygen the way healthy lung tissue does, so even mild fibrosis can leave a person feeling breathless during everyday activities.

Many post-COVID symptoms, including persistent cough and reduced exercise tolerance, have been linked to these fibrotic changes and diminished respiratory function.¹⁷ Hospitalized patients, especially those who needed intensive care, carry a higher risk. A prospective cohort study found that persistent chest symptoms, particularly breathlessness, were reported at roughly twice the rate in people who had been hospitalized compared to those managed at home.¹⁸ Whether post-COVID fibrosis stabilizes, slowly resolves, or progresses over time is still being studied, and new anti-fibrotic treatments are under active investigation.

Brain Fog, Mood, and Neuropsychiatric Symptoms

Cognitive complaints are among the most distressing long COVID symptoms. Patients commonly describe difficulty concentrating, memory lapses, and a mental sluggishness often grouped under the label “brain fog.” Research suggests these problems arise from a combination of neuroinflammation, reduced levels of a protein called BDNF that supports brain plasticity, and disrupted signaling between circulating immune cells and microglia, the brain’s resident immune cells.¹⁹ These changes affect neural remodeling and could have implications not just for adult cognition but also for brain development in younger people.

Depression and anxiety are also strikingly common after COVID-19, and they appear to have both biological and psychological roots. On the biological side, the inflammatory cytokines that flood the body during infection can cross into the brain and interfere with neurotransmitter systems in the regions that regulate mood.²⁰ On the psychological side, the experience of illness itself, including social isolation, uncertainty, and the stress of prolonged disability, adds an independent layer of risk. Experts have recommended multidisciplinary approaches that combine neurological, psychiatric, and rehabilitation support rather than treating these symptoms in isolation.²¹

New-Onset Diabetes and Metabolic Disruption

One of the more alarming findings to emerge from pandemic-era research is that COVID-19 appears to increase the risk of developing diabetes, even in people who had no metabolic problems before getting sick. A systematic review of reported cases found an overall prevalence of new-onset diabetes after COVID-19 of about 1.4%, with type 2 diabetes more common than type 1.²²

The mechanisms appear to involve direct viral damage to the insulin-producing beta cells of the pancreas, persistent inflammation, and the effects of treatments like corticosteroids used during acute illness.²³ The virus may also set up residence in fat tissue and contribute to ongoing insulin resistance through chronic low-grade inflammation.²⁴ The exact size of the added risk is hard to pin down because the pandemic landscape kept changing with new variants, rising vaccination rates, and shifting diagnostic practices. But the signal is consistent enough that clinicians are advised to watch for metabolic changes in people recovering from COVID-19, particularly those with preexisting risk factors like obesity or a family history of diabetes.

Who Is Most at Risk for Long-Term Symptoms

Severity of the initial illness is the clearest risk factor. People who were hospitalized are more likely to develop persistent symptoms, especially chest-related ones, than those who managed their infection at home.¹⁸ But long COVID also affects people who had mild initial infections, which makes it difficult to predict on an individual basis.

Biological sex plays an interesting role. Women are more likely to develop long COVID overall and tend to carry a higher symptom burden. Research into the immune underpinnings has revealed that female and male long COVID patients have genuinely different immune profiles. Women with long COVID show higher rates of exhausted T cells, increased antibody reactions to latent herpesviruses like Epstein-Barr virus, and lower testosterone levels. Men with long COVID tend instead to show changes in innate immune cell populations and elevated levels of certain cytokines.²⁵ A separate study confirmed that female patients with long COVID who also met criteria for ME/CFS showed more severe inflammation, neuroinflammatory gene signatures, and disrupted hormone levels compared to their male counterparts.²⁶ Testosterone levels, regardless of sex, were associated with lower symptom burden, which hints at a hormonal component that cuts across the simple male/female divide.²⁵

The stronger early immune response that may protect women from dying of acute COVID-19, including more robust antibody production, could paradoxically sustain the kind of immune activation that fuels long-term symptoms.²⁷

Does the Variant Matter

The version of SARS-CoV-2 you catch does seem to influence long-term outcomes, though perhaps not in the direction you would expect. When Omicron emerged, its milder acute illness led many people to assume long COVID risk would shrink proportionally. The picture from studies is more complicated. One analysis found that infection with the Omicron variant was associated with lower odds of developing long COVID compared to Alpha, after adjusting for confounders like ICU admission and treatment.²⁸ But another study tracking patients out to 18 months found that those infected with Omicron actually reported worse quality-of-life scores than those infected with the original wild-type virus.²⁹ These seemingly contradictory findings may reflect different study designs, follow-up lengths, and the role of reinfections, which became far more common in the Omicron era. The safest interpretation is that Omicron reduced the per-infection risk of severe long COVID but did not eliminate it, and the sheer number of Omicron infections means the absolute number of long COVID cases remains large.

Children and Long COVID

Children generally weathered acute COVID-19 well, with few severe cases compared to adults. But post-infection complications turned out to be a different story. Multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition where the immune system attacks multiple organs weeks after infection, drew early attention. MIS-C can be frightening in the acute phase but appears to resolve without major long-term consequences in most cases. The more persistent concern is pediatric long COVID, which by definition is an ongoing problem and can be severe enough to disrupt school attendance, physical activity, and social development.³⁰ Fatigue, headaches, and difficulty concentrating are among the most commonly reported symptoms in children with long COVID, and the condition can be especially frustrating to diagnose in younger kids who may not articulate their symptoms clearly.

Vaccination and the Odds of Long COVID

The role of vaccination in preventing long COVID has been an active area of study. Vaccines clearly reduced severe acute illness and death, but their impact on long-term symptoms is harder to quantify. The evidence generally suggests that being vaccinated before a breakthrough infection lowers the odds of developing long COVID, though it does not eliminate the risk entirely.³¹ How much protection different vaccine platforms and booster strategies provide, and whether vaccination after infection helps resolve existing long COVID symptoms, are questions researchers are still sorting out. For now, vaccination remains the most evidence-backed strategy for reducing your chances of long-term complications.

Where Diagnosis and Treatment Stand

One of the most frustrating aspects of long COVID for patients is the lack of a definitive diagnostic test. Routine blood work often comes back normal, which has led some patients to feel dismissed by clinicians. Researchers are actively searching for reliable biomarkers, including inflammatory cytokines, complement proteins, endothelial activation markers, and clotting indices, that could identify long COVID and sort patients into subgroups for targeted treatment.³² Newer research has also looked at the molecular cargo carried by tiny particles shed by cells into the bloodstream, which appear to carry signatures of the inflammatory and clotting abnormalities characteristic of the condition.³³

Treatment remains largely symptom-based. There is no approved drug that cures long COVID. Investigational approaches under study include drugs that target specific inflammatory pathways, anticoagulants aimed at the microclot problem, immune-modulating therapies, and even gut-focused interventions based on the viral persistence hypothesis.³² In the meantime, the most effective care tends to be multidisciplinary: combining physical rehabilitation, pacing strategies for fatigue, cognitive therapy for brain fog, and psychiatric support for mood symptoms, all tailored to the individual patient’s symptom profile.

A Pattern Older Than COVID

It is worth noting that long-lasting symptoms after viral infections are not unique to SARS-CoV-2. Post-acute infection syndromes have been described for over a century following illnesses caused by influenza, Epstein-Barr virus, Lyme disease, and others. What makes long COVID different is partly scale, given how many people were infected worldwide, and partly timing: it arrived in an era with the tools to study it in molecular detail. The mechanisms being uncovered now, including viral persistence, autoimmunity, and endothelial damage, may eventually illuminate why some people never fully bounce back from other infections, too. In that sense, the intense research attention on long COVID could end up benefiting a much larger group of patients whose chronic post-infectious symptoms have historically been poorly understood.

1
PubMed Central. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection
2
PubMed Central. SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways
3
PubMed Central. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection
4
PubMed Central. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19
5
PubMed Central. Three-year outcomes of post-acute sequelae of COVID-19
6
PubMed Central. SARS-CoV-2 Persistence and Cardiovascular Sequelae in the Post-COVID Era
7
PubMed Central. Multiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID
8
PubMed Central. Expression levels of SARS-CoV-2 IgM, IgG, and neutralizing antibodies in a Chinese cohort and detection of peptide-specific antibodies in COVID-19 patients
9
PubMed Central. Damage to endothelial barriers and its contribution to long COVID
10
PubMed Central. Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook
11
Circulation. Detection and Characterization of Fibrin/Amyloid Microclots in Patients With Post-Acute Sequelae of Covid-19
12
PubMed Central. Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An Observational Study
13
PubMed Central. A cardiometabolic perspective on post-exertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID
14
PubMed Central. Long COVID-19 and Postural Orthostatic Tachycardia Syndrome- Is Dysautonomia to Be Blamed?
15
PubMed. Prevalence and Clinical Impact of Postural Orthostatic Tachycardia Syndrome in Highly Symptomatic Long COVID
16
PubMed Central. Post-COVID-19 pulmonary fibrosis: An ongoing concern
17
PubMed. Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis
18
PubMed Central. Long COVID in hospitalized and non-hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study
19
PubMed Central. The Influence of Microglia on Neuroplasticity and Long-Term Cognitive Sequelae in Long COVID
20
PubMed Central. Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment
21
PubMed Central. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis
22
PubMed Central. New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review
23
PubMed Central. SARS-CoV-2 Infection and Pancreatic β Cell Failure
24
PubMed Central. New-Onset Diabetes After COVID-19
25
PubMed Central. Sex differences in symptomatology and immune profiles of Long COVID
26
PubMed Central. Integrated immune, hormonal, and transcriptomic profiling reveals sex-specific dysregulation in long COVID patients with ME/CFS
27
PubMed Central. Female gender is associated with long COVID syndrome: a prospective cohort study
28
PubMed Central. COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants
29
PubMed. Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants
30
PubMed Central. Navigating the Spectrum of Two Pediatric COVID-19 Complications: Multi-System Inflammatory Syndrome in Children and Post-Acute Sequelae of SARS-CoV-2 Infection
31
PubMed Central. Vaccination and COVID-19: impact on long-COVID
32
PubMed Central. Cytokine‐Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies—A Narrative Review
33
PubMed Central. Small extracellular vesicles proteome reveals persistent inflammatory and coagulopathic dysregulation in long-COVID